production rates.
Acta Endocrinol (Copenh)
1989;
121
:
753–758.
26 Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M,
Smith ER. Androgen-stimulated pubertal growth: the effects
of testosterone and dihydrotestosterone on growth hormone
and insulin-like growth factor-I in the treatment of short
stature and delayed puberty.
J Clin Endocrinol Metab
1993;
76
:
996–1001.
27 Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P
et al.
Age-dependent impairment of endothelial progenitor cells
is corrected by growth-hormone-mediated increase of insulin-
like growth-factor-1.
Circ Res
2007;
100
: 434–443.
28 Mulhall JP. Exploring the potential role of neuromodulatory
drugs in radical prostatectomy patients.
J Androl
2009;
30
:
377–383.
29 Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH,
Hartmann U
et al.
Serum levels of human growth hormone
during different penile conditions in the cavernous and
systemic blood of healthy men and patients with erectile
dysfunction.
Urology
2002;
59
: 609–614.
30 Cappelleri JC, Althof SE, Siegel RL, Stecher VJ, Tseng LJ,
Duttagupta S. Association between the Erectile Dysfunction
Inventory of Treatment Satisfaction and the Self-Esteem and
Relationship Questionnaire following treatment with sildena-
fil citrate for men with erectile dysfunction.
Value Health
2005;
8
(Suppl 1): S54–S60.
31 Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG.
Development and validation of the expanded prostate cancer
index composite (EPIC) for comprehensive assessment of
health-related quality of life in men with prostate cancer.
Urology
2000;
56
: 899–905.
32 Rhoden EL, Teloken C, Sogari PR, Souto CA. The relationship
of serum testosterone to erectile function in normal aging men.
J Urol
2002;
167
: 1745–1748.
33 Yassin AA, Saad F. Improvement of sexual function in men
with late-onset hypogonadism treated with testosterone only.
J Sex Med
2007;
4
: 497–501.
34 Rhoden EL, Morgentaler A. Symptomatic response rates to
testosterone
therapy
and
the
likelihood
of
completing
12 months of therapy in clinical practice.
J Sex Med
2010;
7
(1 Part 1): 277–283.
35 Chiang HS, Cho SL, Lin YC, Hwang TI. Testosterone gel
monotherapy improves sexual function of hypogonadal men
mainly through restoring erection: evaluation by IIEF score.
Urology
2009;
73
: 762–766.
36 Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P.
IGF-1, oxidative stress and atheroprotection.
Trends Endo-
crinol Metab
2010;
21
: 245–254.
37 D’Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations
of somatomedin C: further evidence for multiple sites of
synthesis and paracrine or autocrine mechanisms of action.
Proc Natl Acad Sci USA
1984;
81
: 935–939.
38 Chopin LK, Veveris-Lowe TL, Philipps AF, Herington AC.
Co-expression of GH and GHR isoforms in prostate cancer
cell lines.
Growth Horm IGF Res
2002;
12
: 126–136.
39 Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM,
Martin RM. Circulating insulin-like growth factor peptides
and prostate cancer risk: a systematic review and meta-
analysis.
Int J Cancer
2009;
124
: 2416–2429.
40 Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ
et al.
Plasma levels of acid-labile subunit, free insulin-like
growth factor-I, and prostate cancer risk: a prospective study.
Cancer Epidemiol Biomarkers Prev
2010;
19
: 484–491.
41 Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN.
Androgens, growth factors, and risk of prostate cancer: the
Multiethnic Cohort.
Prostate
2010;
70
: 906–915.
42 Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ,
Carter HB. Serum testosterone is associated with aggressive
prostate cancer in older men: results from the Baltimore
Longitudinal Study of Aging.
BJU Int
2010;
105
: 824–829.
43 Morote J, Ramirez C, Gomez E, Planas J, Raventos CX,
de Torres IM
et al.
The relationship between total and free
serum testosterone and the risk of prostate cancer and tumour
aggressiveness.
BJU Int
2009;
104
: 486–489.
IGF-1 levels correlate with sexual dysfunction
AW Pastuszak
et al
226
International Journal of Impotence Research